News &amp; Updates

Treatment with colchicine does not appear to improve functional capacity, respiratory function, or inflammatory markers in adults with long COVID, as shown in a study.

Colchicine flops for long COVID treatment

[Infographics] TRIDENT-1 High ORR, long DoR with repotrectinib in TKI-naïve and -pretreated ROS1+ NSCLC, including Asian patients

The phase I/II TRIDENT-1 trial demonstrates high ORR and durable activity of repotrectinib, a next-generation TKI, in TKI-naïve and -pretreated ROS1+ or NTRK1–3+ locally advanced or metastatic NSCLC, including patients from Asia.

[Infographics] TRIDENT-1 High ORR, long DoR with repotrectinib in TKI-naïve and -pretreated ROS1+ NSCLC, including Asian patients

AI platform for guiding personalized chemotherapy dosing feasible in clinical practice

An artificial intelligence (AI) platform that provides personalized dose recommendations for capecitabine-based chemotherapy regimens for patients with advanced cancer, including those receiving palliative care, proves useful in clinical practice, as shown in a study from Singapore.

AI platform for guiding personalized chemotherapy dosing feasible in clinical practice

Margin ablation averts polyp recurrence

Ablation of endoscopic mucosal resection (EMR) margins effectively prevents the recurrence of colorectal polyps at first surveillance colonoscopy, reveals a study.

Margin ablation averts polyp recurrence

Obesity linked to COVID-19 severity in children during pre-Omicron wave

A recent study has found that individuals with obesity had more severe COVID-19 during the ancestral and pre-Omicron waves, but not during the Omicron wave.

Obesity linked to COVID-19 severity in children during pre-Omicron wave

28 Oct 2025

Neurologic manifestations common in children with COVID-19

Children hospitalized with acute SARS-CoV-2 and multisystem inflammatory syndrome (MIS) tend to experience neurologic manifestations, according to a study in Indonesia.

Neurologic manifestations common in children with COVID-19

Nivolumab bests ipilimumab in head-to-head melanoma trial

The final, long-term results from the phase III CheckMate 238 trial continue to show the superior recurrence-free survival (RFS) benefit of adjuvant nivolumab (NIVO) over ipilimumab (IPI) for resected stage IIIB-C or IV melanoma.

Nivolumab bests ipilimumab in head-to-head melanoma trial

28 Oct 2025

Young-onset diabetes: Novel insights on management

At EmW 2025, Professor Andrea Luk from the Department of Medicine & Therapeutics, the Chinese University of Hong Kong, shared insights and recommendations on management of young-onset diabetes (YoD).

Young-onset diabetes: Novel insights on management

28 Oct 2025

Rifaximin works quicker than LFD in IBS symptom management

In the treatment of patients with irritable bowel syndrome (IBS), rifaximin is as good as the low FODMAP diet (LFD), although the drug provides faster symptom relief and is associated with higher adherence, according to a study.

Rifaximin works quicker than LFD in IBS symptom management